Theravance Secures Long-Term YUPELRI Patent Litigation Settlement

Theravance Biopharma ( (TBPH) ) has shared an update.

On March 27, 2026, Theravance and its partner Mylan reached a settlement with Mankind Pharma and Lifestar Pharma over patent litigation concerning YUPELRI (revefenacin) inhalation solution, which had arisen from Mankind’s bid to launch a generic version before key U.S. patents expired. Under the agreement, Theravance and Mylan granted Mankind a royalty-free, non-exclusive license to sell its generic YUPELRI in the United States starting April 23, 2039, subject to regulatory review, effectively resolving all pending Hatch-Waxman disputes tied to the product and securing a long patent-protected runway for the branded therapy.

The licensed launch date structure preserves Theravance’s and Mylan’s exclusivity and revenue potential from YUPELRI for more than a decade while providing defined entry timing for a future generic competitor. Stakeholders gain greater visibility into the lifecycle of YUPELRI in the U.S. respiratory market, although the settlement remains contingent on review by the U.S. Department of Justice and the Federal Trade Commission, a standard step for agreements of this type.

The most recent analyst rating on (TBPH) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.

Spark’s Take on TBPH Stock

According to Spark, TipRanks’ AI Analyst, TBPH is a Neutral.

The score is supported by strong recent cash flow and a low-leverage balance sheet, with additional help from a low P/E and a generally positive earnings-call outlook on YUPELRI and milestones. These positives are tempered by weak technicals (price below key moving averages, negative MACD) and concerns about sustainability of profitability given negative EBIT and non-operating-driven net income.

To see Spark’s full report on TBPH stock, click here.

More about Theravance Biopharma

Theravance Biopharma, Inc., through subsidiaries including Theravance Biopharma R&D IP, LLC, Theravance Biopharma US, LLC and Theravance Biopharma Ireland Limited, operates in the biopharmaceutical industry and focuses on developing and commercializing respiratory medicines. The company co-develops and licenses products such as YUPELRI (revefenacin) inhalation solution in partnership with Mylan, targeting the U.S. market for chronic obstructive pulmonary disease treatments.

Average Trading Volume: 621,440

Technical Sentiment Signal: Buy

Current Market Cap: $776.5M

Learn more about TBPH stock on TipRanks’ Stock Analysis page.